Pentraxin-3 Predicts Functional Recovery and 1-Year Major Adverse Cardiovascular Events After Rehabilitation of Cardiac Surgery Patients
- 1 January 2012
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Cardiopulmonary Rehabilitation and Prevention
- Vol. 32 (1), 17-24
- https://doi.org/10.1097/hcr.0b013e31823be0f4
Abstract
Inflammatory and vascular markers have proved to be predictors of outcome in myocardial infarction and heart failure. We evaluated several circulating markers of cardiac stress, inflammation, and endothelial function to investigate their ability to predict short-term functional recovery and long-term clinical outcome in heart surgery patients undergoing inpatient rehabilitation. This prospective, multicenter study enrolled 223 patients after heart surgery, included in a 3-week program of standardized and supervised physical training. The association between biomarkers (pentraxin-3 [PTX3], brain natriuretic peptide, high-sensitivity cardiac troponin-T [hs-cTnT] and C-reactive protein [hsCRP], creatine kinase, myoglobin, and urinary albumin excretion [UACR]) and exercise capacity (6-minute walk test, 6MWT) or 1-year incidence of major adverse cardiovascular events (MACE) was tested in models that included biohumoral markers, and clinical and instrumental variables. The patients (69.5% men, mean age of 67 ± 11 years) were enrolled after valvular surgery (52.7%) and 58.6% after coronary artery bypass grafting (CABG). Exercise capacity improved during rehabilitation (6MWT distance from 279 ± 95 to 386 ± 91 m; P < .0001); concentrations of most biomarkers decreased (hsCRP: 79% [P < .0001]; hs-cTnT: 57% [P < .0001]; UACR: 36% [P = .05]). Among the tested markers, PTX3 showed the closest association with 6MWT distance (P = .01) and was the only predictor of MACE, also in the subgroup of CABG patients (OR [95% CI] = 1.14 [1.03–1.27]; P = .015). PTX3, a marker of vascular inflammation and cardiovascular damage, is a predictor of short-term functional recovery and 1-year MACE in patients undergoing rehabilitation after cardiac surgery, regardless of clinical and instrumental parameters.Keywords
This publication has 34 references indexed in Scilit:
- Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarctionAtherosclerosis, 2010
- An Integrated View of Humoral Innate Immunity: Pentraxins as a ParadigmAnnual Review of Immunology, 2010
- Analytical Validation of a High-Sensitivity Cardiac Troponin T AssayClinical Chemistry, 2010
- Prevalence and Prognostic Value of Elevated Urinary Albumin Excretion in Patients With Chronic Heart FailureCirculation: Heart Failure, 2010
- Inflammation in Atherosclerosis From Pathophysiology to PracticeJournal of the American College of Cardiology, 2009
- Six-Minute Walk Test and Cardiopulmonary Exercise Testing in Patients With Chronic Heart FailureCirculation: Heart Failure, 2009
- Associations of Pentraxin 3 With Cardiovascular Disease and All-Cause DeathArteriosclerosis, Thrombosis, and Vascular Biology, 2009
- Effects of an expanded cardiac rehabilitation programme in patients treated for an acute myocardial infarction or a coronary artery by-pass graft operationClinical Rehabilitation, 2008
- The 6-min walking test early after cardiac surgery. Reference values and the effects of rehabilitation programmeEuropean Journal of Cardio-Thoracic Surgery, 2007
- The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular trapsThe Journal of Experimental Medicine, 2007